ES2103274T3 - Metodo de produccion de proteinas de fusion. - Google Patents
Metodo de produccion de proteinas de fusion.Info
- Publication number
- ES2103274T3 ES2103274T3 ES90913419T ES90913419T ES2103274T3 ES 2103274 T3 ES2103274 T3 ES 2103274T3 ES 90913419 T ES90913419 T ES 90913419T ES 90913419 T ES90913419 T ES 90913419T ES 2103274 T3 ES2103274 T3 ES 2103274T3
- Authority
- ES
- Spain
- Prior art keywords
- dna sequence
- place
- union
- restriction
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
LA INVENCION SE REFIERE A METODOS PARA PRODUCIR PROTEINAS DE FUSION COMPRENDIENDO ESTAS ACTIVIDADES BIOLOGICAS DUALES. ESTOS METODOS COMPRENDEN LA PROVISION DE UNA PRIMERA Y DE SEGUNDA SECUENCIA DE ADN QUE CODIFICAN UN PRIMER Y UN SEGUNDO POLIPEPTIDO, RESPECTIVAMENTE, LA DIGESTION DE LA PRIMERA SECUENCIA DE ADN EN UN LUGAR DE RESTRICCION ADYACENTE DE SU TERMINO 3'' O 5'', Y LA LIGADURA DE UNA SECUENCIA ADAPTADORA/ENLAZADORA (1/A) EN EL EXTREMO FINAL DE LA PRIMERA SECUENCIA DE ADN, FORMANDO ASI UN CASET. LA 1/A COMPRENDE, EN UN EXTREMO, ESA PARTE DE LA PRIMERA SECUENCIA DE ADN QUE SE EXTIENDE DESDE UN TERMINO MAS CERCANO DEL LUGAR DE RESTRICCION HASTA EL LUGAR DE RESTRICCION, Y EN EL OTRO EXTREMO, UN LADO DE UN LUGAR DE UNION. UNA CELULA HUESPED EUCARIOTICA SE MODIFICA CON LA CASET Y LA SEGUNDA SECUENCIA DE ADN QUE TIENE, EN UN EXTREMO, UN LADO DE SITIO DE UNION COMPATIBLE CON EL LADO DEL SITIO DE UNION COMPATIBLE CON EL LADO DEL SITIO DE UNION EN LA 1/A. LA CELULA HUESPED MODIFICA ES CULTIVADA PARA EXPRESAR EL ADN MODIFICADO COMO UNA PROTEINA DE FUSION DE CADENA SENCILLA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40988989A | 1989-09-20 | 1989-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2103274T3 true ES2103274T3 (es) | 1997-09-16 |
Family
ID=23622388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96113414T Expired - Lifetime ES2187598T3 (es) | 1989-09-20 | 1990-08-01 | Metodos para producir proteinas de fusion. |
| ES90913419T Expired - Lifetime ES2103274T3 (es) | 1989-09-20 | 1990-08-01 | Metodo de produccion de proteinas de fusion. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96113414T Expired - Lifetime ES2187598T3 (es) | 1989-09-20 | 1990-08-01 | Metodos para producir proteinas de fusion. |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP0493418B1 (es) |
| JP (1) | JP3051162B2 (es) |
| AT (2) | ATE152174T1 (es) |
| AU (1) | AU633357B2 (es) |
| CA (1) | CA2066612C (es) |
| DE (2) | DE69030579T2 (es) |
| DK (2) | DK0765937T3 (es) |
| ES (2) | ES2187598T3 (es) |
| WO (1) | WO1991004329A1 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| WO1992007090A1 (en) * | 1990-10-22 | 1992-04-30 | Genentech, Inc. | Methods for modifying and detecting the effects on the interaction of modified polypeptides and target substrates |
| US5525491A (en) * | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| DE69309472T2 (de) * | 1992-01-23 | 1997-10-23 | Merck Patent Gmbh, 64293 Darmstadt | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
| US6103521A (en) * | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| ES2590912T3 (es) | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| ES2257303T3 (es) * | 1999-07-12 | 2006-08-01 | Genentech, Inc. | Vectores de expresion y procedimientos. |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| MXPA02001417A (es) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| KR20030064275A (ko) | 2000-06-29 | 2003-07-31 | 메르크 파텐트 게엠베하 | 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| RU2003129528A (ru) * | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| EP1383785B1 (en) | 2001-05-03 | 2011-03-16 | Merck Patent GmbH | Recombinant tumor specific antibody and use thereof |
| DK1454138T3 (da) | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| WO2004055056A1 (en) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| ES2305886T3 (es) | 2003-12-30 | 2008-11-01 | Merck Patent Gmbh | Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo. |
| RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
| AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| RU2423381C2 (ru) | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL1966238T3 (pl) | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Warianty interleukiny-12p40 o polepszonej stabilności |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| RU2531754C2 (ru) | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US10071748B2 (en) | 2015-09-17 | 2018-09-11 | Sony Corporation | System and method for providing driving assistance to safely overtake a vehicle |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN110592057B (zh) * | 2019-09-27 | 2022-01-28 | 昆明理工大学 | 嵌合裂解酶ILTphg和编码此酶的多核苷酸 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4771002A (en) * | 1984-02-24 | 1988-09-13 | Lubrizol Genetics, Inc. | Transcription in plants and bacteria |
-
1990
- 1990-08-01 AT AT90913419T patent/ATE152174T1/de not_active IP Right Cessation
- 1990-08-01 AU AU63352/90A patent/AU633357B2/en not_active Ceased
- 1990-08-01 DE DE69030579T patent/DE69030579T2/de not_active Expired - Fee Related
- 1990-08-01 ES ES96113414T patent/ES2187598T3/es not_active Expired - Lifetime
- 1990-08-01 AT AT96113414T patent/ATE228566T1/de not_active IP Right Cessation
- 1990-08-01 ES ES90913419T patent/ES2103274T3/es not_active Expired - Lifetime
- 1990-08-01 EP EP90913419A patent/EP0493418B1/en not_active Expired - Lifetime
- 1990-08-01 CA CA002066612A patent/CA2066612C/en not_active Expired - Lifetime
- 1990-08-01 DK DK96113414T patent/DK0765937T3/da active
- 1990-08-01 DK DK90913419.9T patent/DK0493418T3/da active
- 1990-08-01 DE DE69034022T patent/DE69034022T2/de not_active Expired - Fee Related
- 1990-08-01 JP JP2512474A patent/JP3051162B2/ja not_active Expired - Fee Related
- 1990-08-01 WO PCT/US1990/004301 patent/WO1991004329A1/en not_active Ceased
- 1990-08-01 EP EP96113414A patent/EP0765937B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU633357B2 (en) | 1993-01-28 |
| DE69030579T2 (de) | 1997-11-13 |
| EP0493418B1 (en) | 1997-04-23 |
| DE69034022D1 (de) | 2003-01-09 |
| JP3051162B2 (ja) | 2000-06-12 |
| DE69030579D1 (de) | 1997-05-28 |
| AU6335290A (en) | 1991-04-18 |
| ATE228566T1 (de) | 2002-12-15 |
| DK0493418T3 (da) | 1997-11-03 |
| DK0765937T3 (da) | 2003-03-24 |
| EP0493418A4 (en) | 1992-09-02 |
| JPH05500310A (ja) | 1993-01-28 |
| EP0765937A1 (en) | 1997-04-02 |
| ATE152174T1 (de) | 1997-05-15 |
| CA2066612A1 (en) | 1991-03-21 |
| EP0765937B1 (en) | 2002-11-27 |
| EP0493418A1 (en) | 1992-07-08 |
| CA2066612C (en) | 1998-12-08 |
| WO1991004329A1 (en) | 1991-04-04 |
| ES2187598T3 (es) | 2003-06-16 |
| DE69034022T2 (de) | 2003-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2103274T3 (es) | Metodo de produccion de proteinas de fusion. | |
| FI920923A0 (fi) | Fusionsproteiner, deras framstaellning samt anvaendning. | |
| ES2072900T3 (es) | Expresion elevada de proteinas en levadura. | |
| DK161015C (da) | Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop | |
| ES2046462T3 (es) | Marcadores de activacion de celulas "t". | |
| ATE132902T1 (de) | Humane mangan-superoxiddismutase (hmn-sod) | |
| GR880100198A (el) | Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου. | |
| ES2077666T3 (es) | Proteina de union a fibronectina y su preparacion. | |
| ES2163864T3 (es) | Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas. | |
| ES2153367T3 (es) | Derivados de clorofila y de bacterioclorofila, su preparacion y composiciones farmaceuticas que los contienen. | |
| AR006250A1 (es) | Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico | |
| BR9808769A (pt) | Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio | |
| ATE232237T1 (de) | Herstellung von funktionellen, menschlichen urokinaseproteinen | |
| ES8800267A1 (es) | Un metodo para obtener un peptido biologicamente activo que tiene afinidad para un ligando proteinaceo o su receptor | |
| ES2073735T3 (es) | Nuevos analogos de la cadena b del factor de crecimiento derivado de plaquetas y metodo para su produccion homogenea. | |
| ES2196082T3 (es) | Analagos del factor de crecimiento de queratinocitos. | |
| ES2063370T3 (es) | Agentes mejorados para el control biologico de insectos y metodos de uso. | |
| ES2144399T3 (es) | Clonado del adn de virus de anemia de los pollos. | |
| ES2104596T3 (es) | Nuevos polipeptidos, secuencias de adn que permiten su expresion, metodo de preparacion, y utilizacion. | |
| BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
| ES2026206T3 (es) | Procedimiento para mejorar la expresion de proteina de eucariota. | |
| AR016436A1 (es) | Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades | |
| ES2072868T3 (es) | Proteina capaz de unir la fibronectina y su preparacion. | |
| ES2090357T3 (es) | Una proteina de union a colageno asi como su preparacion. | |
| AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 493418 Country of ref document: ES |